Abbott reported third-quarter 2025 sales of $10.5 billion, an increase of 6.9 percent on a reported basis and 5.5 percent on an organic basis compared to the prior year. Excluding COVID-19 testing-related sales, organic sales growth was 7.5 percent. The company's adjusted operating margin for the quarter was 23.0 percent, reflecting a 40 basis point increase from the previous period. Abbott reaffirmed its full-year 2025 organic sales growth guidance of 7.5 to 8.0 percent excluding COVID-19 testing-related sales, or 6.0 to 7.0 percent including COVID-19 testing-related sales. The board declared a quarterly dividend of $0.59 per share, payable November 17, 2025, to shareholders of record as of October 15, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG97552) on October 15, 2025, and is solely responsible for the information contained therein.